Close

Join us for a day of learning and connecting Register Free Today

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

Developing Effective Immunotherapy for Ovarian Cancer and Other Tumors

On June 17, 2014, George Coukos, M.D., Ph.D., director of the department of oncology at the CHUV, director of the service of developmental therapeutics, and the director of the Ludwig Centre at Lausanne, discussed how current immunotherapy treatment options for women with gynecologic cancers, and how close we are to making these treatments available to more patients.

Prior to his current roles, Dr. Coukos was the Celso Ramon Garcia Professor and Associate Chief of the Division of Gynecologic Oncology, and Director, Ovarian Cancer Research Center, at the University of Pennsylvania Abramson Cancer Center. He is a recognized global leader in ovarian cancer immunotherapy and tumor microenvironment research. His research focuses on understanding the immune system's response to ovarian cancer and other tumor types, and on developing therapies that enhance that response. He is also developing tools to target the tumor vasculature. Dr. Coukos also has extensive experience in designing and conducting phase I clinical cell-based immunotherapy studies, and in the development of cell-based immunotherapy from the laboratory to the clinic.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was generously supported by Agenus. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.

*Immunotherapy results may vary from patient to patient.

Contact Us

National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top